Vascular Dementia

  1. Overview
  2. Epidemiology
  3. Types of Vascular Dementia
  4. Pathophysiology
  5. Risk Factors
  6. Clinical Presentation
  7. Diagnosis
  8. Treatment and Management
  9. Prevention
  10. Prognosis
  11. Recent Research and Advances
  12. Key Research Papers
  13. Connections

Overview

Vascular dementia (VaD) is the second most common cause of dementia after Alzheimer's disease, accounting for approximately 10–20% of dementia cases worldwide. It results from reduced or blocked blood flow to the brain, causing brain cell damage or death through ischemia, infarction, or hemorrhage.

Unlike Alzheimer's disease, which typically follows a slow, continuous downward trajectory, vascular dementia often displays a characteristic stepwise pattern of deterioration — an abrupt worsening tied to a vascular event, followed by a period of relative stability, and then another sudden decline with the next event. However, in the most common subtype (subcortical ischemic vascular dementia), the course can be gradual and insidious, closely mimicking Alzheimer's disease.

In clinical practice, pure vascular dementia is less common than "mixed dementia" — the coexistence of vascular pathology and Alzheimer's disease — which may account for the majority of late-life dementia cases in the elderly. The broader term vascular cognitive impairment (VCI) encompasses the full spectrum, from mild vascular cognitive deficits that do not meet dementia criteria all the way to severe vascular dementia.

Crucially, vascular dementia is one of the most preventable forms of dementia. The same cardiovascular risk factors that cause heart attacks and strokes — hypertension, diabetes, smoking, atrial fibrillation — directly drive vascular brain injury. Sustained control of these risk factors is the main prevention strategy and the cornerstone of management once vascular dementia is established.

Back to Table of Contents

Epidemiology

Vascular dementia affects roughly 1–4% of adults over age 65 in Western countries, with prevalence rising sharply with age and roughly doubling every 5–10 years beyond 65. After Alzheimer's disease, it is the most common form of dementia globally, though methodological differences across studies make precise estimates difficult.

Incidence is slightly higher in men than women, a reversal of the female preponderance seen in Alzheimer's disease. This sex difference likely reflects men's greater burden of stroke, hypertension, and cardiovascular disease at younger ages.

Racial and geographic disparities are striking. Black Americans have substantially higher rates of VaD compared to White Americans, consistent with the greater prevalence of hypertension, diabetes, and stroke in this population. Asian countries, particularly Japan and China, historically show higher rates of VaD relative to Alzheimer's disease compared to Western nations — a pattern attributed to the higher burden of hemorrhagic stroke and small vessel disease in Asian populations, though this gap is narrowing as diet and vascular risk profiles converge.

Post-stroke dementia is especially common: a pooled analysis of 73 papers covering 7,511 stroke patients (Pendlebury and Rothwell 2009) found that about 10% of patients already had dementia before their first stroke, about 10% developed new dementia soon after a first stroke, and more than a third had dementia after a recurrent stroke. After the first year, new dementia appeared at about 3% a year in hospital-based studies. Prior transient ischemic attack (TIA) also carries a meaningfully elevated dementia risk. The stroke-dementia link underscores the shared vascular mechanisms that connect cerebrovascular disease and cognitive decline.

The true population burden of VaD is likely underestimated due to the high prevalence of mixed dementia. Neuropathological series consistently find that a majority of elderly individuals with a clinical diagnosis of Alzheimer's disease also have significant cerebrovascular pathology at autopsy, blurring the boundary between pure vascular dementia and Alzheimer's disease.

Back to Table of Contents

Types of Vascular Dementia

Vascular dementia is not a single entity but a heterogeneous group of conditions sharing the common feature of vascular brain injury causing cognitive decline. The major subtypes differ in mechanism, location of injury, clinical presentation, and imaging findings.

Post-Stroke Dementia (Multi-Infarct Dementia)

The classic and most recognizable form. Cognitive decline occurs after one or more strokes. Large cortical infarcts, multiple small infarcts in different vascular territories, or a single strategically placed infarct in a critical brain region can each cause dementia. The history of overt stroke is an important diagnostic clue. Onset of cognitive decline is typically abrupt, with a temporal relationship to the stroke event.

Strategic Infarct Dementia

A single stroke in a neurologically critical region causes cognitive impairment out of proportion to the overall volume of tissue destroyed. Key strategic locations include the thalamus (especially paramedian thalamic infarcts — bilateral thalamic infarcts from a single artery of Percheron occlusion classically cause severe amnesia, apathy, hypersomnia, and altered consciousness), the angular gyrus, the basal forebrain, the caudate nucleus, the hippocampus, and the genu of the internal capsule. The thalamic variant is particularly well-recognized and may initially be mistaken for encephalitis or metabolic encephalopathy given its acute presentation.

Subcortical Ischemic Vascular Dementia (SIVD)

The most common pure VaD subtype, caused by chronic cerebral small vessel disease. Two overlapping entities are recognized:

Cerebral Amyloid Angiopathy (CAA)

Amyloid-beta protein deposits in the walls of small and medium-sized cortical and leptomeningeal arteries and arterioles. This weakens vessel walls and predisposes to recurrent small cortical hemorrhages, microbleeds (visible as dark "blooming" foci on magnetic resonance imaging gradient echo or SWI sequences), cortical superficial siderosis, and occasionally larger lobar hemorrhages. CAA can cause VaD independently of Alzheimer's disease, though it frequently coexists with AD (amyloid plaques and CAA share the same amyloid-beta protein). CAA is an important cause of cognitive decline in the elderly that is distinct from hypertensive small vessel disease — it favors occipital and parietal lobes, whereas hypertensive microbleeds favor deep structures.

CADASIL

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy is a hereditary small vessel disease caused by mutations in the NOTCH3 gene. Unlike most VaD, CADASIL typically manifests in the 30s and 40s. The classic presentation includes migraine with aura (often the first symptom), recurrent transient ischemic attacks and strokes, mood disturbances, and progressive subcortical dementia. Magnetic resonance imaging shows extensive white matter changes that classically involve the anterior temporal poles and external capsules — a pattern virtually pathognomonic of CADASIL. There is no effective disease-modifying treatment, but cardiovascular risk factor management and antiplatelet therapy are used. CADASIL is the most common monogenic cause of stroke and vascular dementia in adults.

Mixed Dementia

The coexistence of vascular brain injury and Alzheimer's disease pathology. Likely the most common dementia subtype in the elderly, though historically underdiagnosed. Autopsy series consistently find significant cerebrovascular pathology in individuals with clinical Alzheimer's disease and vice versa. Vascular injury may lower the threshold at which amyloid and tau pathology cause clinical dementia — meaning a relatively modest burden of either pathology alone might not produce symptoms, but the two together cross the clinical threshold. Managing vascular risk factors may therefore benefit patients even when Alzheimer's pathology is present.

Back to Table of Contents

Pathophysiology

Cerebral small vessel disease (cSVD) is the central pathological substrate of most vascular dementia. The cascade begins with chronic hypertension and other vascular risk factors that damage the walls of perforating arteries and arterioles supplying the deep white matter, basal ganglia, and thalamus.

The key pathological changes in vessel walls include lipohyalinosis (fibrinoid necrosis and hyaline deposition replacing the normal smooth muscle layer in chronically hypertensive vessels) and arteriolosclerosis (fibrohyaline thickening, tortuosity). These changes narrow vessel lumens, impair autoregulation, and reduce blood flow — particularly during hypotensive episodes or surges in cerebral metabolic demand. The result is ischemia, lacunar infarction, and white matter rarefaction.

Blood-brain barrier (BBB) disruption is increasingly recognized as a critical early event. Damaged small vessels become leaky, allowing plasma proteins, inflammatory cells, and fluid to enter the brain parenchyma. This triggers neuroinflammation, periventricular edema, and progressive demyelination — the white matter changes visible on magnetic resonance imaging as white matter hyperintensities. The magnitude of WMH burden on magnetic resonance imaging correlates with cognitive decline, gait impairment, and future stroke risk.

Hypoperfusion also activates amyloid processing pathways: ischemia upregulates beta-secretase (BACE1) activity, promoting amyloid-beta production, and impairs the clearance mechanisms (interstitial fluid drainage via perivascular spaces and the glymphatic system) that normally remove amyloid-beta from the brain. This provides a mechanistic link explaining why vascular injury and Alzheimer's pathology so frequently coexist and potentiate each other.

The brain regions most vulnerable to vascular injury include the hippocampus (a watershed zone between anterior and posterior circulation, highly sensitive to ischemia), the subcortical white matter (especially periventricular regions at the end-zones of penetrating arteries), and the basal ganglia and thalamus (supplied by small perforating vessels with limited collateral circulation).

The cognitive effects of vascular injury are largely mediated by disruption of subcortical-cortical circuits — particularly the frontal-subcortical loops that mediate executive function, working memory, attention, and processing speed. This explains why executive dysfunction is a hallmark early feature of subcortical VaD, in contrast to the episodic memory impairment that dominates early Alzheimer's disease.

Back to Table of Contents

Risk Factors

Vascular dementia shares its risk factors almost entirely with cardiovascular disease and stroke. This is both the challenge (many risk factors, complex management) and the opportunity (modifiable risk factors offer genuine prevention potential).

Modifiable Risk Factors

Non-Modifiable Risk Factors

Back to Table of Contents

Clinical Presentation

The clinical profile of vascular dementia differs meaningfully from Alzheimer's disease, though the two often coexist and overlap. Recognizing VaD's distinctive features helps guide diagnosis, management, and realistic prognostic conversations.

Cognitive Profile

Behavioral and Mood Features

Neurological Features

Course and Pattern of Decline

The stepwise pattern — abrupt worsening with each new vascular event, some partial improvement, then a stable plateau until the next event — is characteristic of multi-infarct dementia. However, subcortical ischemic vascular dementia (Binswanger disease) often follows a gradual, insidious course that can be difficult to distinguish from Alzheimer's disease clinically without neuroimaging.

Back to Table of Contents

Diagnosis

No single test diagnoses vascular dementia. Diagnosis requires integrating the cognitive history, neurological examination, and neuroimaging findings within established diagnostic frameworks.

Diagnostic Criteria

The most widely used research criteria are the NINDS-AIREN criteria (Roman et al., 1993), which require three elements:

  1. Dementia (significant decline in two or more cognitive domains severe enough to impair daily activities)
  2. Cerebrovascular disease confirmed by neuroimaging (infarcts, white matter lesions)
  3. A temporal relationship between stroke and cognitive decline (onset of dementia within three months of a stroke, or abrupt onset with stepwise course)

More recent VASCOG criteria (2014) and DSM-5 vascular neurocognitive disorder criteria are also used, with somewhat broader definitions that are more appropriate for clinical practice. The VASCOG criteria place particular emphasis on neuroimaging findings and allow diagnosis even without a clinically recognized stroke.

Cognitive Assessment

The Montreal Cognitive Assessment (MoCA) is preferred over the MMSE for detecting VaD because it includes tasks that are sensitive to executive dysfunction and processing speed — the early deficits in VaD that the MMSE misses. Neuropsychological testing provides more detailed characterization of the cognitive profile, which is important for distinguishing VaD from AD and for documenting severity and functional impact.

Neuroimaging

Magnetic resonance imaging is the preferred neuroimaging modality and is essential for a confident VaD diagnosis. Key magnetic resonance imaging findings to assess include:

Computed tomography (CT) scanning can detect large infarcts and hemorrhages but is insensitive to white matter changes and microbleeds; magnetic resonance imaging is strongly preferred when available.

Vascular Workup

Identifying the underlying vascular mechanism guides secondary prevention:

Ruling Out Treatable Causes

Standard laboratory workup (thyroid function, B12, folate, complete blood count (CBC), metabolic panel, syphilis serology if indicated) rules out reversible causes of cognitive decline, which are checked for before a dementia diagnosis is accepted. Normal pressure hydrocephalus (the triad of gait disorder, urinary incontinence, and cognitive decline) is an important differential because it may be treatable with ventriculoperitoneal shunting; it closely mimics subcortical VaD and the two can coexist.

Back to Table of Contents

Treatment and Management

No disease-modifying therapy specifically approved for vascular dementia exists. Treatment centers on three pillars: aggressive management of vascular risk factors to halt further vascular brain injury, secondary stroke prevention, and symptomatic treatment of cognitive and behavioral features.

1. Cardiovascular Risk Factor Control

This is the most important and most evidence-based intervention in VaD management. Unlike Alzheimer's disease, where biological mechanisms driving neurodegeneration cannot yet be meaningfully altered, further vascular brain injury in VaD is genuinely preventable through risk factor control.

2. Secondary Stroke Prevention

3. Pharmacologic Treatment of Cognitive Symptoms

The evidence base for cognitive-enhancing medications in VaD is modest but suggests some benefit:

4. Psychiatric and Behavioral Symptom Management

5. Non-Pharmacologic Rehabilitation

Back to Table of Contents

Prevention

Because vascular dementia shares its risk factors with cardiovascular disease, the same public health strategies that reduce heart attacks and strokes also reduce VaD — making it one of the most genuinely preventable forms of dementia.

Blood Pressure Control

The most evidence-backed single intervention. The SPRINT MIND trial (2019) randomized over 9,000 adults with hypertension to intensive (systolic target below 120 mmHg) versus standard (target below 140 mmHg) blood pressure control and found that intensive control significantly reduced the risk of mild cognitive impairment — the prodrome to dementia (hazard ratio 0.81) — and of mild cognitive impairment or dementia combined (hazard ratio 0.85). Its main target, probable dementia, was not significantly reduced (hazard ratio 0.83; 95% CI 0.67–1.04); the authors note the trial was stopped early and had fewer dementia cases than expected, so it may have been too small to show an effect. The trial excluded people with diabetes or a prior stroke. In the PROGRESS trial (6,105 people with prior stroke or transient ischemic attack, followed about 4 years), perindopril-based treatment lowered dementia by 12%, which was not statistically significant; the 34% reduction applied to the combined outcome of dementia with a recurrent stroke, with no clear effect on dementia without a recurrent stroke. Cognitive decline was 19% lower.

A large trial in rural China (He 2025) enrolled 33,995 people aged 40 or older with uncontrolled high blood pressure in 326 villages. In half the villages, trained village health workers (not doctors, but supervised by primary care physicians) started and adjusted blood pressure medicines to reach below 130/80 mmHg. Over 48 months, systolic pressure fell 22 mmHg more than with usual care, all-cause dementia was 15% lower (risk ratio 0.85; 95% CI 0.76–0.95), and serious adverse events were slightly less frequent.

Secondary Stroke Prevention

Preventing recurrent strokes is the most direct VaD prevention strategy in people who have already had a stroke or transient ischemic attack. This involves antithrombotic therapy, treatment of atrial fibrillation, statin therapy, blood pressure control, and carotid revascularization where indicated. The SPS3 trial specifically examined lacunar stroke secondary prevention. In its blood pressure arm (3,020 patients), a systolic target below 130 mmHg gave a reduction in all stroke that was not statistically significant (hazard ratio 0.81; 95% CI 0.64–1.03), while bleeding inside the brain (intracerebral hemorrhage) fell significantly (hazard ratio 0.37); the authors concluded the lower target is likely to be beneficial.

Diet and Lifestyle

The Mediterranean diet (high in olive oil, vegetables, legumes, fish, whole grains; low in red meat and processed foods) is associated with reduced cardiovascular risk and has been linked to lower dementia incidence in observational studies. Regular aerobic exercise improves blood pressure, insulin sensitivity, lipid profiles, and promotes cerebrovascular health. The EXERT trial reported in 2025: among 296 sedentary older adults with amnestic mild cognitive impairment, 18 months of moderate-to-high intensity aerobic training and low-intensity stretching and balance exercise gave the same cognitive results, and neither group showed cognitive decline over 12 months.

Atrial Fibrillation Screening and Treatment

Screening for atrial fibrillation in older adults and ensuring appropriate anticoagulation can substantially reduce cardioembolic stroke risk and thereby reduce post-stroke dementia. Atrial fibrillation is the most common sustained cardiac arrhythmia in the elderly and remains underdiagnosed.

Treating Sleep Apnea

Obstructive sleep apnea causes intermittent hypoxia and blood pressure surges that damage cerebral vasculature. CPAP treatment reduces cardiovascular risk and may reduce vascular brain injury, though evidence for direct dementia prevention is still accumulating.

Back to Table of Contents

Prognosis

Prognosis in vascular dementia is more variable than in Alzheimer's disease and depends heavily on the success of vascular risk factor management and the prevention of recurrent vascular events.

Median survival after VaD diagnosis is approximately 5 years — similar to Alzheimer's disease — though this varies substantially by age at diagnosis, comorbidity burden, and type of VaD. Some patients stabilize for extended periods with aggressive risk factor control; others decline rapidly with recurrent strokes.

Subcortical ischemic vascular dementia (Binswanger disease) typically follows a slower progression than multi-infarct dementia, though disability accumulates through gait deterioration, falls, and progressive frontal-subcortical dysfunction. Urinary incontinence and falls are major sources of morbidity and caregiver burden.

Post-stroke dementia prognosis is strongly influenced by the size and location of the index stroke, the degree of pre-existing white matter disease, and whether additional strokes occur. Patients with large hemispheric infarcts and significant pre-existing white matter disease have worse prognoses.

Mixed dementia (VaD + Alzheimer's disease) generally carries a worse prognosis than either condition alone, with faster functional decline and shorter survival.

Death in VaD most commonly results from cardiovascular causes (myocardial infarction, recurrent stroke, heart failure) rather than from the dementia itself — reflecting the shared vascular pathology. This is another reason why aggressive cardiovascular risk management extends both quantity and quality of life in VaD.

Importantly, the outlook for individual patients is meaningfully influenced by factors within their control: achieving optimal blood pressure, maintaining physical activity, treating depression, staying socially engaged, and preventing falls. The course of VaD is not fixed: these factors can change it.

Back to Table of Contents

Recent Research and Advances

Research in vascular cognitive impairment has accelerated considerably over the past decade, driven by advances in neuroimaging, biomarkers, and large clinical trials.

Neuroimaging Standardization

The STRIVE criteria (Wardlaw et al., 2013) established standardized terminology and rating methods for magnetic resonance imaging markers of cerebral small vessel disease — including white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, and recent small subcortical infarcts. This has enabled consistent reporting across studies and better understanding of how these markers relate to cognitive outcomes.

Blood Biomarkers for Vascular Brain Injury

Plasma neurofilament light chain (NfL), a marker of neuroaxonal damage, is elevated in VaD and other neurodegenerative conditions. Plasma GFAP (glial fibrillary acidic protein) reflects astrocyte injury. These biomarkers are being evaluated as tools for monitoring disease progression and treatment response. Additionally, circulating markers of blood-brain barrier integrity (such as plasma albumin ratio) and endothelial dysfunction are under active investigation.

The Glymphatic System

The perivascular glymphatic system — a brain-wide network of perivascular spaces that facilitates bulk flow of cerebrospinal fluid (CSF) and interstitial fluid, clearing metabolic waste products including amyloid-beta — is impaired in cerebral small vessel disease. Enlarged perivascular spaces visible on magnetic resonance imaging may reflect glymphatic dysfunction. Sleep (particularly deep slow-wave sleep) is a major driver of glymphatic clearance, providing a mechanism by which sleep disorders worsen vascular cognitive impairment.

Vascular-Alzheimer's Intersection

The interaction between vascular pathology and Alzheimer's disease is an active research frontier. Evidence from SPRINT MIND and other trials showing that vascular risk factor control can reduce cognitive impairment even in the context of Alzheimer's pathology suggests that addressing vascular contributions to dementia remains beneficial even in "AD." The two-hit model — where vascular injury lowers the threshold at which amyloid and tau pathology cause clinical dementia — has important treatment implications.

CADASIL Genetics and Novel Monogenic VaD

Beyond CADASIL, mutations in COL4A1 and COL4A2 (encoding collagen IV, a component of vascular basement membranes) are increasingly recognized as causes of hereditary cerebral small vessel disease with stroke and dementia. HTRA1 mutations cause CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), another hereditary VaD with earlier onset and alopecia. Next-generation sequencing is revealing a broader genetic architecture for cerebral small vessel disease than previously recognized.

Back to Table of Contents

Key Research Papers

  1. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–1706. — PubMed PMID: 26595643 · doi:10.1016/S0140-6736(15)00463-8
  2. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260. — PubMed PMID: 8094895 · doi:10.1212/wnl.43.2.250
  3. Dichgans M, Leys D. Vascular cognitive impairment. Circ Res. 2017;120(3):573–591. — PubMed PMID: 28154105 · doi:10.1161/CIRCRESAHA.116.308426
  4. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–838. — PubMed PMID: 23867200 · doi:10.1016/S1474-4422(13)70124-8
  5. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61(4):479–486. — PubMed PMID: 12939421 · doi:10.1212/01.wnl.0000078943.50032.fc
  6. SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553–561. — PubMed PMID: 30688979 · doi:10.1001/jama.2018.21442
  7. Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326–3344. — PubMed PMID: 31248555 · doi:10.1016/j.jacc.2019.04.034
  8. SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–825. — PubMed PMID: 22931315 · doi:10.1056/NEJMoa1204133
  9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or TIA. Lancet. 2001;358(9287):1033–1041. — PubMed PMID: 11589932 · doi:10.1016/S0140-6736(01)06178-5
  10. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643–653. — PubMed PMID: 19539236 · doi:10.1016/S1474-4422(09)70127-9
  11. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol. 2005;4(11):752–759. — PubMed PMID: 16239182 · doi:10.1016/S1474-4422(05)70221-0
  12. Qiu C, Fratiglioni L. Aging without dementia is achievable: current evidence from epidemiological research. J Alzheimers Dis. 2018;62(3):933–942. — PubMed PMID: 29562544 · doi:10.3233/JAD-171037
  13. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–1075. — PubMed PMID: 12742805 · doi:10.1001/archinte.163.9.1069
  14. SPS3 Study Group; Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507–515. — PubMed PMID: 23726159 · doi:10.1016/S0140-6736(13)60852-1
  15. Baker LD, Pa JA, Katula JA, et al. Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study. Alzheimers Dement. 2025;21(4):e14586. — PubMed PMID: 40271888 · doi:10.1002/alz.14586
  16. He J, Zhao C, Zhong S, et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nat Med. 2025;31(6):2054–2061. — PubMed PMID: 40258956 · doi:10.1038/s41591-025-03616-8
  17. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006–1018. — PubMed PMID: 19782001 · doi:10.1016/S1474-4422(09)70236-4

PubMed Topic Searches

Search PubMed for current research on vascular dementia and related topics:

  1. PubMed: Vascular dementia review
  2. PubMed: Cerebral small vessel disease
  3. PubMed: NINDS-AIREN vascular dementia criteria
  4. PubMed: Vascular cognitive impairment treatment
  5. PubMed: White matter hyperintensities dementia
  6. PubMed: Post-stroke dementia
  7. PubMed: Subcortical ischemic vascular dementia
  8. PubMed: CADASIL NOTCH3 mutation
  9. PubMed: Mixed dementia Alzheimer vascular
  10. PubMed: Blood pressure control dementia prevention
  11. PubMed: Cholinesterase inhibitors vascular dementia
  12. PubMed: Cerebral amyloid angiopathy

Back to Table of Contents

Connections

Back to Table of Contents